91844-20-1

Basic information

• Product Name: 5-bromo-1-methyl-1H-indole-2-carboxylic acid
• Synonyms: 5-bromo-1-methyl-1H-indole-2-carboxylic acid;5-Bromo-2-(ethoxycarbonyl)-1-methyl-1H-indole
• CAS NO: 91844-20-1
• Molecular Formula: C₁₂H₁₂BrNO₂
• Molecular Weight: 282.13318
• Mol File: 91844-20-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 83～85℃
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-bromo-1-methyl-1H-indole-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-1-methyl-1H-indole-2-carboxylic acid(91844-20-1)
• EPA Substance Registry System: 5-bromo-1-methyl-1H-indole-2-carboxylic acid(91844-20-1)

Safety Data

• Hazardous Substances Data: 91844-20-1(Hazardous Substances Data)

Usage

Uses

Ethyl 5-Bromo-1-methyl-1H-indole-2-carboxylate is a useful reactant for copper-catalyzed cross-coupling of indoles with H-phosphinate.

Upstream product

• 74-88-4 methyl iodide 
• 16732-70-0 ethyl 5-bromoindolecarboxylate 
• 74-83-9 methyl bromide 

Downstream Products

• 1399296-00-4 C₁₂H₁₁BrINO₂ 
• 1607826-90-3 ethyl 5-bromo-1-methyl-3-[methyl(phenyl)amino]-1H-indole-2-carboxylate 
• 1607826-89-0 ethyl 5-bromo-1-methyl-3-[(2,4,6-trimethylphenyl)amino]-1H-indole-2-carboxylate 
• 1607826-88-9 ethyl 5-bromo-1-methyl-3-[2-(1-methylethyl)phenyl]amino-1H-indole-2-carboxylate 
• 1607826-87-8 ethyl 5-bromo-1-methyl-3-[(4-sulfamoylphenyl)amino]-1H-indole-2-carboxylate 
• 1607826-86-7 ethyl 5-bromo-1-methyl-3-[(4-nitrophenyl)amino]-1H-indole-2-carboxylate 
• 1607826-85-6 ethyl 5-bromo-3-[4-(methoxycarbonyl)phenyl]amino-1-methyl-1H-indole-2-carboxylate 
• 1607826-84-5 ethyl 5-bromo-3-[(4-methoxyphenyl)amino]-1-methyl-1H-indole-2-carboxylate 
• 1607826-83-4 ethyl 5-bromo-3-[(4-bromophenyl)amino]-1-methyl-1H-indole-2-carboxylate 
• 1607826-82-3 ethyl 5-bromo-1-methyl-3-[(4-methylphenyl)amino]-1H-indole-2-carboxylate 
• 1607826-80-1 ethyl 5-bromo-3-[(4-iodobenzyl)amino]-1-methyl-1H-indole-2-carboxylate 
• 1607826-79-8 ethyl 5-bromo-3-[2-(4-chlorophenyl)ethyl]amino-1-methyl-1H-indole-2-carboxylate 
• 1607826-75-4 ethyl 5-bromo-1-methyl-3-[2-(tritylsulfanyl)ethyl]amino-1H-indole-2-carboxylate 
• 1607826-66-3 ethyl 3-[benzyl(methyl)amino]-5-bromo-1-methyl-1H-indole-2-carboxylate 

Relevant articles and documents

Tandem Rh(II) and Chiral Squaramide Relay Catalysis: Enantioselective Synthesis of Dihydro-β-carbolines via Insertion to C-H Bond and Aza-Michael Reaction

An efficient tandem rhodium(II)/squaramide relay catalysis of readily accessible indole derivatives and N-sulfonyl-1,2,3-triazoles has been developed for the enantioselective synthesis of dihydro-β-carbolines in good yield and enantioselectivity. The developed reaction involves selective insertion of in situ generated azavinyl rhodium carbene onto the C3-H bond of indole derivatives and subsequent squaramide-catalyzed enantioselective intramolecular aza-Michael reaction. Furthermore, the potential of the strategy was demonstrated through the ready conversion to potent tetrahydro-β-carbolines and the tetracyclic alkaloid core structure.

INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF

Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

INDOLINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide: a compound or a pharmacologically acceptable salt thereof which inhibits a retinoic acid receptor-related orphan receptor and, due to suppression of Th-17 cell differentiation and/or suppression of IL-17 production, is effective for treatment and/or prevention of psoriasis, multiple sclerosis, rheumatic arthritis, inflammatory bowel disease, Sjogren's syndrome, systemic lupus erythematosus, chronic obstructive pulmonary disease, asthma, or colon cancer; and a pharmaceutical composition containing the compound. SOLUTION: Provided are a compound represented by the following formula or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing the compound. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT